This course has expired. View available courses.
Endocrinology
Intensifying Therapy: Primary Care Patient Case (RCGP)
This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.
DURATION
30 min
PROFESSION
Physician, Nursing, Student, Specialist
# OF CREDITS
0.5
ACCREDITATION
RCGP
EXPIRY DATE
2023-03-07
Type 2 diabetes is a common condition managed in primary care. Although clinical practice guidelines recommend specific targets for blood pressure, lipids and HbA1c, primary care research has demonstrated only a small portion of patients with type 2 diabetes are meeting these targets. With the management of type diabetes, clinicians are still encouraged to work with patients to meet glycaemic targets, but there is an increased focus on a holistic assessment of the patient to reduce the risk of cardiorenal outcomes. This module will focus on providing recommendations on the intensification of antihyperglycaemic therapy beyond metformin in people with type 2 diabetes.
This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.
Faculty
Dirk Pilat, FRCGP, PgDipGP, BSc, MA
David Strain, MD, FRCP, MBChB
Toni Hazell, MBBS, BSc, MRCGP, DFSRH, Dip GU med, DRCOG, DCH
Learning objectives
Upon successful completion of this continuing education module, the participant will be better able to:
- Individualize antihyperglycaemic therapy for the person with type 2 diabetes
- Review how the most recently published antihyperglycaemic agent trials are potentially changing the management of people with type 2 diabetes
- Discuss the selection of antihyperglycaemic agents in patients with cardiovascular and chronic kidney disease